Momelotinib
Momelotinib, sold under the brand name Ojjaara, is an anticancer medication used for the treatment of myelofibrosis. It is a Janus kinase inhibitor and it is taken by mouth. The most common adverse reactions include dizziness, fatigue, bacterial infection, hemorrhage, thrombocytopenia, diarrhea, and nausea. Momelotinib was approved for medical use in the United States in September 2023. Medical uses 
Momelotinib is indicated for the treatment of intermediate or high-risk myelofibrosis in adults with anemia. Pharmacology

Pharmacodynamics 
It is an inhibitor of Janus kinases JAK1 and JAK2, acting as an ATP competitor with IC50 values of 11 and 18 nM, respectively. The inhibitor is significantly less active towards other kinases, including JAK3 (IC50 = 0.16 μM). References

External links 
 
 

Benzamides
4-Morpholinyl compounds
GSK plc brands
Nitriles
Non-receptor tyrosine kinase inhibitors
Protein kinase inhibitors
Aminopyrimidines